<SEC-DOCUMENT>0001171843-20-004804.txt : 20200707
<SEC-HEADER>0001171843-20-004804.hdr.sgml : 20200707
<ACCEPTANCE-DATETIME>20200707162350
ACCESSION NUMBER:		0001171843-20-004804
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200707
FILED AS OF DATE:		20200707
DATE AS OF CHANGE:		20200707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		201016318

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_070720.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report: July 7, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name
into English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59120 Loos, France</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Address
of principal executive office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; text-align: left">&#9746; Form 20-F</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">&#9744; Form 40-F</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT LIST </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release dated July 7, 2020.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 7, 2020</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD>
    <TD STYLE="vertical-align: top; width: 19%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><FONT STYLE="font-size: 14pt"><B>GENFIT:
Enhances Board of Directors with Two Strategic Appointments</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 38.4pt; margin-bottom: 0pt; color: #005478"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 38.4pt; margin-bottom: 0pt; color: #005478"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 38.4pt; margin-bottom: 0pt; color: #005478"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005278"><B>Lille
(France), Cambridge (Massachusetts, United States), July 7, 2020 </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;
GENFIT (Nasdaq and Euronext: GNFT)</FONT></B>, a late-stage biopharmaceutical company dedicated to improving the lives of patients
with metabolic and liver diseases, today announced, following its annual Shareholders Meeting, the appointment of Ms. Katherine
Kalin and Mr. Eric Baclet to the company&rsquo;s Board of Directors. Together, they bring more than 50 years of combined pharmaceutical
experience and deep subject matter expertise that will aid in the next phase of Genfit&rsquo;s growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005278"><B>Pascal
Prigent, CEO of GENFIT</B></FONT>, noted: &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>We are delighted to
announce the appointments of Katherine and Eric to the board. Both bring a wealth of highly relevant life science industry experience.
Ms. Kalin has extensive strategic and financial management experience in both pharmaceutical and diagnostic solutions, with a deep
understanding of the U.S. market. Mr. Baclet has a broad experience covering therapeutic drug development, as well as commercial
management in several markets, including China. Both will bring strong knowledge bases and strategic insights as the company works
to determine the next corporate steps that will shape its transformation.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Ms. Kalin&rsquo;s healthcare
industry expertise spans diagnostics, medical devices, and pharmaceuticals. Ms. Kalin is currently a director on the boards of
Clinical Genomics, a molecular diagnostic firm, Brown Advisory, a strategic advisory and investment firm, and Primari Analytics,
a startup in artificial intelligence. From 2012-17, Ms. Kalin led corporate strategy at Celgene, a global biopharmaceutical company,
for 5 1/2 years. Prior to that, Ms. Kalin held executive leadership roles in marketing, sales, strategy and new business development
at Johnson &amp; Johnson (J&amp;J) from 2002 to 2011. Prior to J&amp;J, Ms. Kalin served as a Partner at McKinsey and Company,
a global management consulting firm, where she negotiated and led consulting assignments, as a strategic advisor to pharmaceutical,
medical device and other healthcare companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Mr. Eric Baclet has over
30 years of experience with Eli Lilly in international drug development, management, and commercialization, all expertise he gained
as President and General Manager of Lilly Italia, General Manager of Lilly China, VP of Global Marketing, and Executive Directorship
of International Marketing, to name a few. Throughout his tenure at Eli Lilly, Mr. Baclet spearheaded international drug launches
across multiple geographies, and led multi-disciplinary teams involved in biopharmaceutical value-chain management in more than
seven countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005278"><B>Jean-Fran&ccedil;ois
Mouney, Chairman of the Board</B></FONT>, added: <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&quot;The Board is
thrilled to welcome Katherine and Eric. We look forward to working with Pascal and the GENFIT team to help the company</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 9pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-size: 9pt"><B>GENFIT </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="color: rgb(112,111,97); width: 10%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>build value and succeed
in its development programs in therapeutic areas with high unmet medical need.&quot;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">GENFIT is a late-stage biopharmaceutical
company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a pioneer
in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two
decades. Its drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (&ldquo;RESOLVE-IT&rdquo;)
as a potential treatment for NASH and GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in patients with PBC. As
part of GENFIT&rsquo;s comprehensive approach to clinical management of patients with NASH, the Company is also developing a new,
non-invasive blood-based diagnostic technology, NIS4&trade;, which, if approved, could enable easier identification of patients
with at-risk NASH. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees.
GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext&rsquo;s regulated
market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; color: #005478"><B>FORWARD LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This press release contains certain forward-looking
statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT,
including statements about the Company&rsquo;s next development and transformation steps, its potential to create value, and new
Directors&rsquo; contribution to value creation. The use of certain words, including &ldquo;believe,&rdquo; &ldquo;potential,&rdquo;
&ldquo;expect&rdquo; and &ldquo;will&rdquo; and similar expressions, is intended to identify forward-looking statements. Although
the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company&rsquo;s
management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause
actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These
risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related
to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory
authorities of its drug and diagnostic candidates and the Company&rsquo;s continued ability to raise capital to fund its development,
as well as those risks and uncertainties discussed or identified in the Company&rsquo;s public filings with the French Autorit&eacute;
des</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 38.4pt; margin-bottom: 0pt; color: #005478"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 38.4pt; margin-bottom: 0pt; color: #005478"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 9pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-size: 9pt"><B>GENFIT </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="color: rgb(112,111,97); width: 10%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">march&eacute;s financiers
(&ldquo;AMF&rdquo;), including those listed in Section 2.1 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s 2019
Universal Registration Document filed with the AMF on May 27, 2020 under n&deg; D.20-0503, which is available on GENFIT&rsquo;s
website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S.
Securities and Exchange Commission (&ldquo;SEC&rdquo;), including the Company&rsquo;s 20-F dated May 27, 2020. In addition, even
if the Company&rsquo;s results, performance, financial condition and liquidity, and the development of the industry in which it
operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.
These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable
law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as
a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #005478"><B>CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #005478"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENFIT
</B></FONT>| Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Naomi EICHENBAUM &ndash; Investor Relations
| Tel: +1 (617) 714 5252 | investors@genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PRESS
RELATIONS </B></FONT>| Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">H&eacute;l&egrave;ne LAVIN &ndash; Press
relations | Tel: +333 2016 4000 | helene.lavin@genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: rgb(112,111,97)"><FONT STYLE="font-size: 9pt"><B>GENFIT
                           </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P>



</TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 9pt; color: #706F61">3</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" P\# 2(  A$! Q$!_\0
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M':=AAIWW#_=' _K7GY-!RQ::Z79Z.:34<,T^MC:N[RWT^SEN[J58H(E+N[=
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M#I__ (,F_P#C5.^W^*?^@#I__@S;_P"-4<C_ *8>T79_<;I%,9:Q/MWBG_H
MZ?\ ^#)O_C5--_XH_P"@#I__ (,F_P#C5'(_Z8>T79_<;!&#3Q6";[Q1_P!
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M..34Z#BJT3;CFK24@)!3L4@IU( I*6FF@89HS244Q :2@FF[J '4N:9NI=U
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MKSV]Z]7U/P]I6K6$=C>6:/;Q?ZM%)39QCC&,5DV/P[\-V5RLZ6)D=3E1-(6
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MI1Y:,,A@.E $1ADC(,BD#U'-.N'SA?;H:GBF=T#/P!Z5)+<PW2!'1 XZ$=:
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M>J\)._KWHHH0'0Z0[D[2S%?3/%9FJHJW(VJ!\W8444+<"74N+&W X&*S8?\
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M0=:**8AZU*M%%(!PIU%% Q:***0!1110,*#110(2BBBF M(:** &FHVZ444
M0/3%HHJ)%1)5J&__ ./&3\/YBBBHELS2/Q(Y^7O38/\ 6445S+<ZI;&U;?=%
M6QTHHKJ6QQO<0]*KR@444F-&;.HW'@5 JC=T'Y445GU-31MQTK3C^[115P,I
$[G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
